Effect of supplement involved ferulic acid, glycerophosphocholine, ginkgo leaf extract and vitamin C on mild cognitive impairment. -Before after study

Not Applicable

• Conditions: Mild Cognitive Impairment

• Registration Number: JPRN-UMIN000036381
• Lead Sponsor: FANCL Corporation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-04-04
• Study Completion: 2020-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1) Subjects who constantly use Kampo preparation affecting cognitive function or dementia. 2) Subjects who constantly use supplements preparation affecting cognitive function or dementia. 3) Subjects who have psychiatric disorder affecting cognitive function or dementia with the exception of complete remission. 4)Subjects who take medical treatment for psychoneurosiswith antipsychotic drug. 5) Subjects with metabolic disease affecting cognitive function or dementia. 6) Subjects with liver disease, renal disease or hypoactivity of renal function (eGFR<=20 mL/min). 7) Subjects with uncontrolled type 2 diabetes or received insulin treatment. 8) Subjects with chronic obstructive lung disease and oxygen therapy in home or FEV1<30%. 9) Subjects with essential hypertension or uncontrolled hyperlipidemia. 10) Subjects who have medical history of gastrointestinal surgery or hospitalization for head injury within 10 years. 11) Subjects who have history of intracerebral hemorrhage, subarachnoid hemorrhage, cardiac hypertrophy, cardiac failure, ischemic heart disease, nephrosclerosis, aortic dissection or cerebral infarction. 12) Subjects with structural diseases with a possibility related to recognition dysfunction in the head MRI image acquired within 1 year before agreement acquisition or the first time check point. 13) Subjects who take medical treatment for cancer. 14) Subjects who are planned to participate in other clinical study. 15) Subjects who are judged as unsuitable for the study by the investigator for other reason.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MMSE (0day,90days and 180 days)

Secondary Outcome Measures

Name	Time	Method
ABC dementia scale POMS2 Blood apolipoprotein E (0day,90days and 180 days)